Menarini Group Announces New Data on Elacestrant at 2023 ESMO Breast Cancer Congress and 2023 ASCO Annual Meeting – Elacestrant has been approved by the FDA for treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine
Menarini Group and Radius Health Announce Global License Agreement for the Development and Commercialization of Elacestrant – - Elacestrant further strengthens Menarini's global oncology portfolio, recently bolstered by the acquisition of Stemline Therapeutics in the U.S.- Radius will receive $30M as an upfront payment and up to $320M in additional milestones along with tiered low to mid-teen percentage royaltiesThe